BICO Group AB (publ) (BICO.ST) has a MoatMap StockRank of 54/100 based on Quality (38/100), Value (66/100), and Momentum (37/100) factor scores. The current signal is HOLD. BICO Group has suffered from severe governance issues, cash burn, and integration challenges, making it unsuitable for a high-quality compounder portfolio.
BICO Group AB is a global pioneer in bioconvergence, combining biology, engineering, and computer science to develop technologies for 3D bioprinting, liquid handling, and tissue diagnostics. The company's instruments and consumables are widely used by pharmaceutical giants and academic institutions to accelerate drug discovery and reduce animal testing. BICO maintains a strong market position through its extensive patent portfolio, global distribution, and a high-margin recurring revenue stream from proprietary consumables.
| Price | $1.86 |
| Market Cap | $144M |
| P/E (Forward) | -33.92 |
| Price/Book | 0.79 |
| Return on Equity | -69.3% |
| Return on Invested Capital | -71.1% |
| Debt/Equity | 42.93 |
| Gross Margin | 51.5% |
| Operating Margin | -27.6% |
| Revenue Growth | -1.4% |
| Free Cash Flow | $7M |
BICO Group AB (publ) operates in the Medical Devices industry, part of the Healthcare sector (Sweden).